The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Open accessThe DOI matches its Crossref record; 119 of the 140 references it cites were found in a registry or an index; 9 of the 77 sources its claims cite were checked for support.
Abstract
OBJECTIVE: The objective of the study was to develop clinical practice guidelines for the diagnosis of Cushing's syndrome. PARTICIPANTS: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. CONSENSUS PROCESS: Consensus was guided by systematic reviews of evidence and discussions. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage the Task Force incorporated needed changes in response to written comments. CONCLUSIONS: After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with a high discriminatory value, and patients with adrenal incidentaloma. We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test). We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test. Patients with concordant abnormal results should undergo testing for the cause of Cushing's syndrome. Patients with concordant normal results should not undergo further evaluation. We recommend additional testing in patients with discordant results, normal responses suspected of cyclic hypercortisolism, or initially normal responses who accumulate additional features over time.
Overview
CoChat Summary
TL;DR
This Endocrine Society guideline recommends case detection for Cushing's syndrome only in selected high-risk groups, initial testing with one of four high-accuracy tests, and confirmatory second testing before cause-directed evaluation. It emphasizes excluding exogenous glucocorticoids first and notes that most recommendations rest on very low- to low-quality evidence.
Key findings
- Exclude exogenous glucocorticoid exposure before biochemical testing (1QQQQ); test patients with multiple and progressive features, unusual features for age, children with decreasing height percentile and increasing weight, or adrenal incidentaloma compatible with adenoma, and recommend against widespread testing in other groups.
- Initial testing should use one of: urine free cortisol (at least two measurements), late-night salivary cortisol (two measurements), 1-mg overnight dexamethasone suppression test, or 48-h 2 mg/d dexamethasone suppression test; recommend against random serum cortisol/plasma ACTH, urinary 17-ketosteroids, insulin tolerance test, loperamide test, and cause-directed tests for initial diagnosis.
- Reported test performance includes late-night salivary cortisol sensitivity 92–100% and specificity 93–100%; pediatric UFC sensitivity about 89%; 1-mg DST at a 1.8 µg/dL cutoff sensitivity >95% with specificity 80%, rising to >95% specificity at a 5 µg/dL threshold; LDDST sensitivity 96% and specificity 70%; dexamethasone-CRH sensitivity 98% and specificity 60%.
- Special-population recommendations: use UFC and avoid dexamethasone testing in pregnancy; avoid dexamethasone testing with enzyme-inducing antiepileptics; suggest 1-mg overnight DST rather than UFC in severe renal failure; suggest UFC or midnight salivary cortisol rather than DSTs in suspected cyclic Cushing's; suggest 1-mg DST or late-night cortisol rather than UFC in adrenal incidentaloma.
Methods
- A six-member Task Force appointed by The Endocrine Society's Clinical Guidelines Subcommittee, including a chair, five additional experts, a methodologist, and a medical writer, received no corporate funding or remuneration; consensus was guided by systematic reviews and discussions and approved sequentially by Society bodies and members.
- Recommendations used the GRADE approach: strong recommendations phrased “we recommend” with number 1, weak recommendations “we suggest” with number 2; evidence quality ranged from QEEE (very low) to QQQQ (high), informed by best available research evidence and systematic reviews/meta-analyses of test accuracy.
- The guideline presents evidence, values, and remarks linked to each recommendation; technical remarks often reflect the panel's unsystematic observations applied to a typical patient.
Limitations
- Stated: the majority of recommendations are based on very low- to low-quality evidence, with limited data linking diagnostic strategies to patient-important outcomes and no higher-quality direct evidence available.
- Stated: published data often come from larger tertiary referral centers and may be biased toward more diagnostically challenging cases, higher pretest probability, and greater disease severity, potentially giving an overly sanguine view of test performance in unselected populations.
- Evident from the text: this is a consensus guideline rather than a primary study, and some technical recommendations rest on unsystematic panel observations; data on treating mild/subclinical Cushing's syndrome and adrenal incidentaloma are described as limited and conflicting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 4 Not valid · 37 Not checked · 33 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another study of 86 consecutive obese subjects referred to an endocrine clinic with diabetes mellitus, hypertension, and/or the polycystic ovary syndrome found a 5.8% incidence of Cushing's syndrome (35).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.3 Evidence
What the sources say
- Partly supportedcites [35] 35. Ness-Abramof R, Nabriski D, Apovian CM, Niven M, Weiss E, Shapiro MS, Shenkman L 2002 Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese. Obes Res 10:1217-1221 sourceExperimental — accuracy not yet measured
The Patients section describes 86 obese patients referred to an endocrine clinic, and the Results report five Cushing’s syndrome diagnoses—5/86, or approximately 5.8%, though the paper prints 5.7%. The copy does not say the patients were consecutive. It also reports that 51 had obesity alone, so diabetes, hypertension, and polycystic ovary disease do not describe the whole group. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The salivary glands express 11-hydroxysteroid dehydrogenase type 2 (11-HSD2), which converts the biologically active cortisol to inactive cortisone (75).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Remarks for late-night salivary cortisol
What the sources say
- Supportedcites [75] 75. Smith RE, Maguire JA, Stein-Oakley AN, Sasano H, Takahashi K, Fuku- shima K, Krozowski ZS 1996 Localization of 11-hydroxysteroid dehydro- genase type II in human epithelial tissues. J Clin Endocrinol Metab 81:3244 - 3248 source
The paper reports 11β-HSD2 in the ducts of human parotid and submandibular salivary glands (Abstract; Discussion, p. 3247). It describes the enzyme as inactivating glucocorticoids and discusses salivary cortisol-to-cortisone ratios (Introduction; Discussion, p. 3247), supporting the stated function. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Overall, the evidence in adults suggests that the accuracy of this test is similar to that of UFC (2).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Evidence for late-night salivary cortisol
What the sources say
- Supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 source
Table 3 (Conclusions; page unavailable) reports broadly similar pooled diagnostic likelihood ratios for midnight salivary cortisol and UFC. The Summary of findings notes that evidence for salivary cortisol is more limited, consistent with the citing sentence’s cautious wording. (LLM, conf=0.88)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When the assay upper limit of normal is used as a criterion, the overall evidence supports the diagnostic accuracy of UFC in adults suspected of having Cushing's syndrome (2,51).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.1 Evidence for use of UFC
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Summary of findings says UFC has substantial evidence supporting its use to detect Cushing’s syndrome, and the pooled results table reports diagnostic accuracy across 14 UFC studies. The Subgroup analyses section identifies an assay-upper-limit cutoff, but the reported UFC estimate is pooled across studies rather than shown specifically for that cutoff. The Conclusions also limit the apparent accuracy to referral practices enriched with patients with Cushing’s syndrome; performance in usual clinical practice remains unclear. Page numbers were not available in our copy. (LLM, conf=0.83)
- Supportedcites [51] 51. Pecori Giraldi F, Ambrogio AG, De Martin M, Fatti LM, Scacchi M, Cav- agnini F 2007 Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series. J Clin Endocrinol Metab 92:4123- 4129 source
The UFC results (p. 2) report 91.2% specificity in Cushing’s syndrome suspects when values above the assay’s reference range were considered abnormal. The Discussion (p. 5) identifies that threshold as the assay’s upper limit of normal and describes UFC as having superior diagnostic performance. The study assessed specificity, rather than diagnostic accuracy across all measures. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The four recommended tests have acceptable diagnostic accuracy when the suggested cutoff points are used (2,30).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4 Evidence
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Conclusions state that commonly used tests appear highly accurate in referral practices with samples enriched for Cushing’s syndrome, but that their performance in usual clinical practice is unclear. The Data extraction section says the review used cutoffs chosen by the primary studies, selecting those with the best performance when several were available; it does not establish accuracy specifically at the suggested cutoff points. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [30] 30. Batista DL, Riar J, Keil M, Stratakis CA 2007 Diagnostic tests for children who are referred for the investigation of Cushing syndrome. Pediatrics 120: e575-e586 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims · 3 with their cited sources checked
Create a free account to see all 82 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, accurate serum cortisol measurement is essential for the correct diagnosis and management of adrenal pathologies.”
From Serum cortisol: an up-to-date assessment of routine assay performance (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the reliability of almost all markers of HPA axis activity, particularly ACTH and 24-h urinary free cortisol (UFC), is low (3,14,23)”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, UFC should not be considered an adequate screening test for SH and should be used in combination with other tests or in specific populations (1,14).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some authors have proposed higher (3 or 8 mg) dexamethasone doses (40,46,54,56), which however did not show a better performance (14,23,66).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measured
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“biochemical hypercortisolism is present in a large fraction (up to 10%).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“Libe et al. (32) reported 18%; Terzolo et al. (21) quoted 5-20%, depending on referral bias and diagnostic tests and criteria.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > Subsequent evaluation
“3.9.1 We suggest the additional use of the dexamethasone-CRH test or the midnight serum cortisol test in specific situations (Fig. 1, 1QEEE).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > METHOD OF DEVELOPMENT OF EVIDENCE-BASED RECOMMENDATIONS
“strong recommendations use the phrase "we recommend" and the number 1, and weak recommendations use the phrase "we suggest" and the number 2.”
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“with expertise in development and implementation of evidencebased guidelines (1).”
BackgroundCushing, H. (1964) · Journal of Neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 851 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundThe Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Self-citationGold, P. W., Loriaux, D. L., Roy, A., Kling, M. A., Calabrese, J. R., Kellner, C. H., Nieman, L. K., Post, R. M., Pickar, D., Gallucci, W., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605223142101 · Cited by 766
Self-citationThe natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundTESTS OF PITUITARY-ADRENAL SUPPRESSIBILITY IN THE DIAGNOSIS OF CUSHING'S SYNDROME*
LIDDLE, G. W. (1960) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-20-12-1539 · Cited by 735
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“These data are consistent with the increased cardiovascular mortality and morbidity reported in patients with iatrogenic Cushing’s syndrome secondary to the chronic use of synthetic corticosteroids (15).”
ResultMeasurements of Serum Free Cortisol in Critically Ill Patients
Hamrahian, A. H., Oseni, T. S., & Arafah, B. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa020266 · Cited by 726 · cited 1×
“are associated with decreased serum cortisol values (39, 46).”
BackgroundMorbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622 · cited 2×
“0-fold, compared with the general population (4, 5).”
BackgroundIncidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study1
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt-Rasmussen, U., Hagen, C., Jørgensen, J., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 619 · cited 6×
“Because some patients with Cushing’s disease demonstrate suppressibility to dexamethasone, use of this diagnostic criterion J Clin Endocrinol Metab, May 2008, 93(5):1526–1540 jcem.”
BackgroundInfluential
Cited by
Items 1,301–1,400 of 2,716
Etiology-, Sex-, and Tumor Size-Based Differences in Adrenocorticotropin-Dependent Cushing Syndrome
Walia, R., Dutta, A., Gupta, N., Bhansali, A. K., Pivonello, R., Ahuja, C. K., Dhandapani, S., Dutta, P. R., Bhadada, S. K., Simeoli, C., et al. (2020) · Endocrine Practice · doi:10.1016/j.eprac.2020.11.014 · Cited by 9
Left-right differences in adrenal vein sampling for primary aldosteronism
Miyoshi, A., Wada, N., Baba, S., Obara, S., Takahashi, B., Usubuchi, H., & Terae, S. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej19-0372 · Cited by 11
“8 μg/dL in overnight 1-mg dexamethasone suppression test (1-mg DST) were also excluded [10].”
BackgroundDavison, S. L. (2009) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181a8f914 · Cited by 8
“Salivary cortisol, for example, has been described as having high diagnostic accuracy for the screening of Cushing syndrome and has been recommended in clinical practice guidelines for screening for this condition.(2) However, as Flyckt et al report, the current technology is such that the accuracy of”
MethodAn accurate, non-invasive approach to diagnose Cushing’s syndrome in at-risk populations
Cardoso, E. M. L., Arregger, A. L., Monardes, G., & Contreras, L. N. (2013) · Steroids · doi:10.1016/j.steroids.2013.02.005 · Cited by 8
“0 nM) obtained in this study are in agreement with data based on compilation studies [10].”
Ceccato, F., Bavaresco, A., Ragazzi, E., Barbot, M., Boscaro, M., Basso, D., Scaroni, C., & Antonelli, G. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae517 · Cited by 7
Ozkaya, H. M., Keskin, F. E., Tuten, A., Korkmaz, E., Oktay, H. Z., & Kadioglu, P. (2017) · Endocrine Practice · doi:10.4158/ep171887.or · Cited by 7
“Cushing’s syndrome’s diagnosis was established according to recent guidelines (12).”
BackgroundMeunier, S. M., Groessl, M., Reusch, C. E., Boretti, F. S., & Sieber‐Ruckstuhl, N. S. (2021) · BMC Veterinary Research · doi:10.1186/s12917-021-02890-1 · Cited by 7
Giampietro, R. R., Cabral, M. V. G., Pereira, E. G., Machado, M. C., Vilar, L., & Nogueira, V. D. S. N. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1332120 · Cited by 10
“3%(range,1.5% – 26.7%)ofpituitaryincidentalomasinthegeneral population (10) and in up to 38% of patients with EAS (11), the differential diagnosis between CD and EAS has been recommended (7, 12), especially when a lesion with a size of 6 mm is observed on pituitary magnetic resonance imaging (MRI).”
BackgroundInfluentialNowak, E., Vogel, F., Braun, L., Zopp, S., Rubinstein, G., Schilbach, K., Bidlingmaier, M., Zimmermann, P., Thorsteinsdottir, J., Schweizer, J. R. D. O. L., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae097 · Cited by 10
Cushing syndrome in paediatric population: who and how to screen
Chioma, L., Patti, G., Cappa, M., & Maghnie, M. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02452-w · Cited by 15
“In order to reduce intra-patient variability and to provide a better diagnostic accuracy, it is now recognised that at least two UFC measurements should be performed in subjects suspected of CS [27, 38, 40, 41].”
Who and how to screen for endogenous hypercortisolism in type 2 diabetes mellitus or obesity
Guarnotta, V., Giordano, C. S. D. S., & Reimondo, G. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02455-7 · Cited by 13
Measurement of salivary thyroid hormones using the LC-MS/MS technique in a clinical setting
Sawicka‐Gutaj, N., Glinicki, P., Nijakowski, K., Bromińska, B., Ostrowska, M., Szatko, A., Sobol, Z., Kowalski, K., Wilk, P., Zgliczyński, W., et al. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188241277414 · Cited by 9
Lin, B. C., Melnikov, V., Guo, S., Cao, Z., Ye, Z., Ye, Z., Ji, C., Chen, J., Wang, J., Zhang, H., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae139 · Cited by 8
Nerubenko, E., Ryazanov, P. A., Kuritsyna, N., Paltsev, A. A., Ivanova, O. A., Grineva, E. N., Kostareva, A. A., Dmitrieva, R. I., & Tsoy, U. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312886 · Cited by 10
“CD was diagnosed according to the current guidelines [48,49].”
Calcaterra, V., Magenes, V. C., Fratangeli, N., Nigro, G., Fabiano, V., Mendolicchio, L., & Zuccotti, G. (2024) · Frontiers in Pediatrics · doi:10.3389/fped.2024.1415061 · Cited by 11
Approach to the Patient With Cyclical Cushing Syndrome
Ferrière, A., Nunes, M. L., & Tabarin, A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae864 · Cited by 9
Headache in pituitary adenomas: frequency, characteristics and outcome after treatment
Scaf, C. R., Altoé, A., Ventura, N., Vincent, M. B., Kasuki, L., & Gadelha, M. R. (2025) · Pituitary · doi:10.1007/s11102-025-01504-5 · Cited by 10
“All patients with macroadenomas or microadenomas between 6 and 9 mm were screened for hypopituitarism according to current recommendations and those diagnosed with adrenal insufficiency and hypothyroidism were under replacement [ 34 , 35 , 36 , 37 , 38 , 39, 40 ].”
Hamidi, O., Salama, B., Wang, T. S., Findling, J. W., Zhang, C. D., Carroll, T. B., Dream, S. Y., Sada, A., Balderrama-Brondani, V., Dogra, P., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf515 · Cited by 12
“…clinical and biochemical scoring systems (13) to grade severity based on Endocrine Society guidelines on the diagnosis of Cushing syndrome (14), European Society of Endocrinology clinical guidelines on adrenal incidentaloma (15), systematic review on MACS (16), and expert opinion…”
Self-citationTheodorou, A., Tan, E. C., Bakkar, M. A., Reiner, A. S., Sazo, M., Cohen, M. A., Lin, A. L., Tabar, V. S., & Geer, E. B. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf598 · Cited by 10
Ceccato, F., Terzolo, M., Gatto, F., Cannavò, S., Bianchi, A., Isidori, A. M., Colao, A. A. L., Ferone, D., Aimaretti, G., Giraldi, F. P., et al. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02758-3 · Cited by 12
Zhang, Q., Cai, Y., Liu, Y., Yao, B., Sharma, P., Ruoff, E., Ma, Z., Zopp, S., Wu, Y., Abreu, A. P., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00396-1 · Cited by 8
Cushing's disease -- assessing the efficacy of transsphenoidal surgery.
Witek, P., Zieliński, G., Maksymowicz, M., & Kamiński, G. (2012) · PubMed · Cited by 7
Stalla, G. K., Ciato, D., & Dimopoulou, C. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0664-7632 · Cited by 10
Cushing's syndrome: Consequences of late diagnosis after bariatric surgery
Pedro, J. M. P., Belo, S., Guerreiro, V. A., Ferreira, M. J., Salazar, D. A., Costa, C. F., Esteves, C., Pereira, J., Freitas, P., & Carvalho, D. M. (2020) · Clinical Case Reports · doi:10.1002/ccr3.2694 · Cited by 6
Garrahy, A., Forde, H. E., O’Kelly, P., McGurren, K., Zia-Ul-Hussnain, H. M., Noctor, E., Tormey, W. P., Smith, D., Dennedy, M. C., Bell, M., et al. (2020) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-020-02334-z · Cited by 9
Witek, P., Maksymowicz, M., Szamotulska, K., Piaścik, A., Wojciechowska-Luźniak, A., Stasiewicz, A., Witek, J., & Zieliński, G. (2020) · Folia Neuropathologica · doi:10.5114/fn.2020.102438 · Cited by 7
“The diagnosis of Cushing’s disease was made according to standard criteria [29].”
MethodResultMotomura, N., Yamazaki, Y., Koga, D., Harashima, S., Gao, X., Tezuka, Y., Omata, K., Ono, Y., Morimoto, R., Satoh, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042174 · Cited by 8
“All of the cases were clinically diagnosed as adrenal CS [26].”
BackgroundBray, D. P., Rindler, R. S., Dawoud, R. A., Boucher, A. B., & Oyesiku, N. M. (2022) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2021.12.006 · Cited by 9
Hung, K., Lee, B., Chen, P., Liu, K., Chang, C., Wu, V., & Lin, Y. (2023) · Endocrine Connections · doi:10.1530/ec-23-0121 · Cited by 9
“Patients who failed to suppress cortisol secretion (>1.8 µg/dL, (50 nmol/L)) were stratified into the ACS group; otherwise, they were placed into the non-ACS group (13, 25, 26).”
InfluentialSun, H., Wu, C., Hu, B., & Xie, G. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2282183 · Cited by 10
Predicting delayed remission in Cushing’s disease using radiomics models: a multi-center study
Zhang, W., Zhang, D., Liu, S., Wang, H., Liu, X.-H., Dai, C., Fang, Y., Fan, Y., Wei, Z., Feng, M., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1218897 · Cited by 8
Cushing's Syndrome in Pregnancy Secondary to Adrenocortical Adenoma: A Case Series and Review
Wang, Y., An, Y., Hou, X., Xu, Y., Li, Z., Liu, X., Zheng, F., Sun, M., Han, R., Lü, C., et al. (2024) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.474 · Cited by 7
Mu, D., Xia, Q., Ma, Y., Wang, X., Gao, Y., Ma, X., Xie, S., Hou, L., Zhang, Q., Zhao, F., et al. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.04.008 · Cited by 9
Thyroid function spectrum in Cushing’s syndrome
Yu, P., Yuan, H., Chen, H., & Li, X. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01614-4 · Cited by 8
“Accurate functional diagnosis determines the prognosis of the disease [1, 2].”
BackgroundMethodWho and how to screen for endogenous hypercortisolism in patients with mood disorders
Ferrante, E., Simeoli, C., Mantovani, G., & Pivonello, R. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02457-5 · Cited by 10
“…mood disorders of discriminatory signs of CS, with high specificity, such as proximal myopathy, facial plethora, striae rubrae and easy bruising [13], after the exclusion of glucocorticoid exogenous administration, may strengthen the decision to screen these patients for CS. Similarly, the…”
InfluentialEndocrine changes (beyond diabetes) after bariatric surgery in adult life.
Savastano, S., Somma, C. D., Pivonello, R., Tarantino, G., Orio, F., Nedi, V., & Colao, A. (2013) · PubMed · doi:10.3275/8880 · Cited by 7
Evolution, Global Warming, Smart Phones, and Late-Night Salivary Cortisol
Findling, J. W. (2014) · Endocrine Practice · doi:10.4158/ep14451.co · Cited by 7
Self-citationCushing's disease presenting with gastrointestinal perforation: a case report
Hara, T., Akutsu, H., Yamamoto, T., Ishikawa, E., Matsuda, M., & Matsumura, A. (2013) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-13-0064 · Cited by 7
Quantitative Analysis of Salivary Cortisol Using LC-MS/MS
Zhang, Y. V. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3182-8_9 · Cited by 7
Enfermedades de las glándulas suprarrenales
Rabinovich, I. H., & de Victoria, E. O. M. (2014) · Elsevier eBooks · doi:10.1016/b978-84-9022-595-0.00020-x · Cited by 7
Daniel, E., & Newell-Price, J. D. C. (2017) · F1000Research · doi:10.12688/f1000research.10968.1 · Cited by 10
“Loss of sensitivity to the negative cortisol feedback at the level of the pituitary and hypothalamus is a key feature of CD and is used for biochemical diagnosis 14 .”
BackgroundSelf-citationBilateral vertebral artery dissection revealing Cushing's syndrome
Ilie, I., Vouillarmet, J., Decaussin‐Petrucci, M., Jeannin-Mayer, S., Lifante, J. C., Thivolet, C. H., & Marchand, L. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.02.001 · Cited by 7
Yılmaz, N., Tazegül, G., Bozoğlan, H., Sarı, R., Özdem, S., Altunbaş, H., & Balcı, M. K. (2018) · Journal of Investigative Medicine · doi:10.1136/jim-2018-000752 · Cited by 8
Kline, G. A., & Chin, A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803412-5.00005-7 · Cited by 10
Koracevic, G. P., Stojkovic, M., Lović, D. B., Pavlović, M., Kostić, T. L., Kutlesic, M. S., Mićić, S., Koraćević, M., & Djordjević, M. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666181005122339 · Cited by 9
Carcinoid tumor causing ileoceccal intussusception in an adult patient
Zhang, J., Tran, D. H., Uradomo, L. T., Verceles, A. C., & Chow, R. D. (2019) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2019.1601058 · Cited by 7
Reliability of adrenal computed tomography in predicting the functionality of adrenal incidentaloma
Mansour, A., Al-Waeli, D. K., & Haddad, N. (2020) · Nigerian Postgraduate Medical Journal · doi:10.4103/npmj.npmj_156_19 · Cited by 9
Ahmed, S. F., Bapir, R., Fattah, F. H., Mahmood, A. G., Salih, R. Q. M., Salih, A. M., Tahir, S. H., & Kakamad, F. H. (2022) · International Journal of Surgery Case Reports · doi:10.1016/j.ijscr.2022.107038 · Cited by 7
Surgical treatment of adrenal tumors during pregnancy
Bartz-Kurycki, M. A., Dream, S. Y., & Wang, T. S. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09744-7 · Cited by 9
Epidemiology and blood parameter changes in Cushing’s syndrome — a population-based study
Mangion, J., Imbroll, M. G., Craus, S., Vassallo, J., & Gruppetta, M. (2022) · HORMONES · doi:10.1007/s42000-022-00384-9 · Cited by 9
“Diagnosis of CS was confirmed by an endocrine specialist in accordance with the Endocrine Society diagnostic criteria of CS [15], by evaluating clinical features, biochemical data, imaging, and histopathological reports.”
MethodCardiovascular risk factors in mild adrenal autonomous cortisol secretion in a Caucasian population
Adamska, A., Ulychnyi, V., Siewko, K., Popławska‐Kita, A., Szelachowska, M., Adamski, M., Buczyńska, A., & Kretowski, A. J. (2022) · Endocrine Connections · doi:10.1530/ec-22-0074 · Cited by 11
de Eulate-Beramendi, S. Á., Ortega, A. C., Ollero, L., Niemann, L. K., Fernandez-Miranda, J. C., Bruneau, M., Berhouma, M., Cavallo, L. M., Cornelius, J. F., Daniel, R. T., et al. (2022) · Brain and Spine · doi:10.1016/j.bas.2022.100917 · Cited by 8
Heterogeneous circulating miRNA profiles of PBMAH
Hara, K., Murakami, M., Niitsu, Y., Takeuchi, A., Horino, M., Shiba, K., Tsujimoto, K., Komiya, C., Ikeda, K., Tsuiki, M., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1073328 · Cited by 6
Primary bilateral macronodular adrenal hyperplasia: A series of 32 cases and literature review
Castro, M. A., & Reincke, M. (2023) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2023.04.005 · Cited by 10
Ueland, G. Å., Methlie, P., Heie, A., Stokland, A. M., Dahle, A. L., Sævik, Å. B., Løvås, K., & Husebye, E. S. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad076 · Cited by 11
Iatrogenic Cushing’s Syndrome Caused by Adulteration of a Health Product with Dexamethasone
Mikhail, N. E., Kurator, K., Martey, E. B., et al. (2022) · International Journal of Endovascular Treatment and Innovative Techniques · doi:10.61797/ijetit.v3i1.194 · Cited by 7
Paediatric Cushing’s disease: long-term outcome and predictors of recurrence
Savage, M. O., & Ferrigno, R. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1345174 · Cited by 15
Self-citationWang, M., Qin, L., Bao, W., Xu, Z., Han, L., Yan, F., & Yang, W. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02295-x · Cited by 8
“This study included a total of 29 patients with endogenous CS who fulfilled the diagnostic criteria recommended by clinical practice guidelines [19, 20] before and underwent clinically referred CCTA from January 1, 2017 to January 1, 2022.”
InfluentialSpatial Transcriptomic Analysis of Pituitary Corticotroph Tumors
Oliver, J. D., Faucz, F. R., Padilla, C. J., Floudas, C. S., Chittiboina, P., Quezado, M., & Tatsi, C. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae064 · Cited by 8
da Silva, R. M. G., Pinto, E. M., Goldman, S. M., Andreoni, C., Vieira, T. C., & Abucham, J. (2010) · Pituitary · doi:10.1007/s11102-010-0260-5 · Cited by 6
“Criteria for the laboratory confirmation of CS and for the differentiation between adrenal and pituitary Cushing’s have been derived from studies of adult patients [23].”
BackgroundVasilev, V., Matrozova, J., Elenkova, A. P., & Zacharieva, S. (2014) · Open Medicine · doi:10.2478/s11536-013-0199-9 · Cited by 10
“001 compared to patients with NFAA), followed by pheochromocytoma patients – 50 mm [38-57] (p=0.”
MethodResultInfluentialArihara, Z., Sakurai, K., Osaki, Y., Fukazawa, H., Yamada, S., Inoshita, N., Murakami, O., Ohba, K., & Takahashi, K. (2011) · Endocrine Journal · doi:10.1507/endocrj.ej11-0038 · Cited by 7
“It is known that DDAVP test is considerably useful as the screening for ACTH-dependant Cushing’s syndrome [3-6].”
BackgroundNew treatment guidelines on Cushing's disease
Arnaldi, G., & Boscaro, M. (2009) · F1000 Medicine Reports · doi:10.3410/m1-64 · Cited by 10
“being applied to a large population [18].”
BackgroundRodzinna częściowa lipodystrofia w diagnostyce różnicowej zespołu policystycznych jajników
Lewandowski, K. C., Lewiñski, A., Dąbrowska, K., Jakubowski, L., & Gach, A. (2015) · Endokrynologia Polska · doi:10.5603/ep.2015.0067 · Cited by 9
Saroka, R. M., Kane, M. P., Robinson, L. R., & Busch, R. S. (2016) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s39997 · Cited by 7
Tirosh, A., Lodish, M. B., Papadakis, G. E., Lyssikatos, C., Belyavskaya, E., & Stratakis, C. A. (2016) · Hormone and Metabolic Research · doi:10.1055/s-0042-115644 · Cited by 8
“The diagnostic algorithm for Cushing syndrome (CS) is divided into 2 separate stages, starting with establishing the diagnosis of endogenous CS, followed by identifying its cause [1].”
BackgroundMethodAdrenocortical carcinoma masquerading as Cushing's disease
Jarial, K. D., Walia, R., Kumar, S., & Bhansali, A. (2017) · BMJ Case Reports · doi:10.1136/bcr-2016-217519 · Cited by 7
Secondary amenorrhea: Diagnostic approach and treatment considerations
Pereira, K. C., & Brown, A. J. (2017) · The Nurse Practitioner · doi:10.1097/01.npr.0000520832.14406.76 · Cited by 11
Yener, S., Seçil, M., Demir, Ö., Saydam, B. Ö., & Yörükoğlu, K. (2018) · Clinical Endocrinology · doi:10.1111/cen.13587 · Cited by 11
Balla, A., Quaresima, S., Palmieri, L., Ortenzi, M., Sbardella, E., Puliani, G., Isidori, A. M., Guerrieri, M., & Paganini, A. M. (2018) · Surgical Endoscopy · doi:10.1007/s00464-018-6601-6 · Cited by 7
Lages, A. D. S., Frade, J. G., Oliveira, D., Paiva, I., Oliveira, P., Rebelo‐Marques, A., & Carrilho, F. (2019) · Acta Médica Portuguesa · doi:10.20344/amp.11265 · Cited by 7
The Multifarious Cushing’s – Lessons from a Case Series
Ilie, I., Ciubotaru, V., Tulin, A., Hortopan, D., Caragheorgheopol, A., Purice, M., Neamtu, C., Elian, V. I., Banica, A., Oprea, L., et al. (2019) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2019.261 · Cited by 7
Roberts, R. O., Maria, M. V. D., Brigham, D., & Hsu, S. C. (2019) · Pediatric Cardiology · doi:10.1007/s00246-019-02248-3 · Cited by 7
Evaluation of various confirmatory tests for the diagnosis of aldosterone-producing adenoma
Kidoguchi, S., Sugano, N., Kawauchi, R., Nakashima, D., Hayashi-Ishikawa, N., Tokudome, G., & Yokoo, T. (2020) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320320919610 · Cited by 7
Diagnostic value of salivary cortisol in 1-mg dexamethasone suppression test
Belaya, Z. E., Malygina, A. A., Grebennikova, T. A., Il'yin, A. V., Rozhinskaya, L. Y., Fadeev, V. V., Mel'nichenko, G. A., & Dedov, I. I. (2020) · Obesity and metabolism · doi:10.14341/omet10117 · Cited by 8
Corticotroph hyperplasia and Cushing disease: diagnostic features and surgical management
Catalino, M. P., Meredith, D. M., Girolami, U. D., Tavakol, S., Min, L., & Laws, E. R. (2020) · Journal of neurosurgery · doi:10.3171/2020.5.jns201514 · Cited by 12
Patients with pheochromocytoma exhibit low aldosterone renin ratio-preliminary reports
Yamada, T., Fukuoka, H., Hosokawa, Y., Odake, Y., Yoshida, K., Matsumoto, R., Bando, H., Okada, Y., Hirota, Y., Iguchi, G., et al. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00620-6 · Cited by 7
Ehrlich, K., Morbach, C., Reiter, T., Heuschmann, P. U., Hannemann, A., Faßnacht, M., Störk, S., Hahner, S., & Deutschbein, T. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00665-7 · Cited by 7
“Care will be taken that former diagnosis of CS was made according to published guidelines [22].”
MethodMifepristone as Bridge or Adjunct Therapy in the Management of Challenging Cushing Disease Cases
Chang, A. Y., Mirfakhraee, S., King, E. E., Mercado, J. U., Donegan, D. M., & Yuen, K. C. J. (2021) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551421994102 · Cited by 7
Detomas, M., Altieri, B., Schlötelburg, W., Appenzeller, S., Schlaffer, S. M., Coras, R., Schirbel, A., Wild, V., Kroiß, M., Sbiera, S., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.731579 · Cited by 9
Bevan, J. S. (2013) · Clinical Medicine · doi:10.7861/clinmedicine.13-3-296 · Cited by 7
Yan, F., Zeng, J., Chen, Y., Cheng, Y., Yu, P., Zang, L., Chen, K., Gu, W., Du, J., Guo, Q., et al. (2022) · Endocrine · doi:10.1007/s12020-022-03077-w · Cited by 8
“BAA were diagnosed according to AVS adjusted by plasma aldosterone and were subsequently confirmed by postoperative pathology [7, 10].”
Zinc alpha-2 glycoprotein is overproduced in Cushing's syndrome
Escoté, X., Aranda, G. B., Mora, M., Casals, G., Enseñat, J., Vidal, Ó., Esteban, Y., Halperín, I., & Hanzu, F. A. (2017) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2016.10.002 · Cited by 7
Danese, E., Salvagno, G. L., Guzzo, A., Scurati, S., Fava, C., & Lippi, G. (2017) · Biochemia Medica · doi:10.11613/bm.2017.031001 · Cited by 8
Hannah‐Shmouni, F., Gubbi, S., Spence, J. D., Stratakis, C. A., & Koch, C. A. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.08.010 · Cited by 8
Ramírez‐Rentería, C., Espinosa-de-los-Monteros, A. L., Etual, E.-C., et al. (2020) · Case Reports in Endocrinology · doi:10.1155/2020/4768281 · Cited by 7
Persistent Comorbidities in Cushing’s Syndrome after Endocrine Cure
Resmini, E. (2014) · Advances in Endocrinology · doi:10.1155/2014/231432 · Cited by 9
“Subclinical hypercortisolism (SH) is defined as a status of altered hypothalamic pituitary—adrenal (HPA) axis secretion in the absence of the classical signs or symptoms of an overt cortisol excess [18, 19].”
BackgroundBenelli, E., Marradi, M., Sciarroni, E., Cosmo, C. D., Bagattini, B., Ghianda, S. D., Simoncini, T., Fruzzetti, F., Tonacchera, M., & Fiore, E. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02404-4 · Cited by 6
Diagnostic and management challenges in paediatric Cushing's syndrome
Joshi, K., Taliou, A., & Stratakis, C. A. (2024) · Clinical Endocrinology · doi:10.1111/cen.15096 · Cited by 10
Marques, A. C. D. S., Brito, B., Fontes, J. G. B., Carneiro, G. R. A., Rebelo, J. F. D., Moraes, A. B., Neto, L. V., & Padilha, M. C. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.120055 · Cited by 7
Cela, E., Alcubierre, D. D., & Sbardella, E. (2024) · Clinical Endocrinology · doi:10.1111/cen.15182 · Cited by 11
“However, in some cases the clinical picture of CD is much less clear and can be misleading, especially in patients with mild or cyclical hypercortisolism [119, 136].”
Rouf, S., Berrabeh, S., Zarraa, L., & Latrech, H. (2024) · Journal of Medicine and Life · doi:10.25122/jml-2024-0015 · Cited by 6
Walia, R., Chakraborty, A. M., Pandey, S., Rana, N., Kumar, R., Ahuja, C. K., Singh, H., Dhandapani, S., Sahoo, S. K., Chhabra, R., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07304-0 · Cited by 8
“CS was diagnosed as per the Endocrine Society Clinical Practice Guidelines [10].”
InfluentialZhou, W., Zheng, S., Ye, L., Su, T., Xie, J., Jiang, L., Jiang, Y., Zhong, X., Wu, L., Zhou, W., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf269 · Cited by 7
Wu, N., Wu, N., Wang, N., & Zhu, Y. (2025) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2025.102039 · Cited by 7
Perry, L., & Medbak, S. (2013) · Elsevier eBooks · doi:10.1016/b978-0-08-097037-0.00057-9 · Cited by 6
Parksook, W. W., Laichuthai, N., & Sunthornyothin, S. (2020) · Case Reports in Endocrinology · doi:10.1155/2020/2946868 · Cited by 8
Cushing's Syndrome Behind Hypokalemia and Severe Infection: A Case Report
Elias, C., de Oliveira, D. M., Silva, M. M., & Lourenço, P. (2022) · Cureus · doi:10.7759/cureus.32486 · Cited by 6
“It is recognized and accepted that hospitalization may induce a state of pseudo-CS [2]; however, the magnitude of cortisol values both in 24h urine (more than three times the upper reference range) and in the serum favor a real CS.”
BackgroundSulu, C., Gül, N., Tanrıkulu, S., Doğanşen, S. Ç., Öztürk, F. Y., Saraç, B., Ersungur, E. B., Aydın, E. T., Şahin, S., Özkaya, H. M., et al. (2023) · Pituitary · doi:10.1007/s11102-023-01342-3 · Cited by 6
“All the tertiary referral centers involved in the present study followed internationally agreed guidelines in the treatment and follow-up of patients with CD [49].”
BackgroundStifel, U., Vogel, F., Caratti, G., Reincke, M., & Tuckermann, J. P. (2023) · Hypertension · doi:10.1161/hypertensionaha.123.21185 · Cited by 6
Metadata
- Authors
- Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M.
- Affiliations
- National Institutes of Health (US)
- Massachusetts General Hospital (US)
- Medical College of Wisconsin (US)
- University of Sheffield (GB)
- Queen Mary University of London (GB)
- University of Birmingham (GB)
- Mayo Clinic (V.M.M.), Rochester, Minnesota 55905
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-05-01
- Volume
- 93
- Issue
- 5
- Pages
- 1526-1540
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC2386281
- OpenAlex
- W1990995386
- Cited by
- 2,718
- References
- 140
- Citations by year
- 2026: 159 · 2025: 173 · 2024: 173 · 2023: 148 · 2022: 212 · 2021: 199 · 2020: 195 · 2019: 165 · 2018: 150 · 2017: 148 · 2016: 158 · 2015: 156 · 2014: 134 · 2013: 139 · 2012: 114
- FWCI
- 70.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD008833)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- Cushing's syndrome, diagnosis, hypercortisolism, adrenal incidentaloma, dexamethasone suppression test, late-night salivary cortisol, urine cortisol
- MeSH terms
- Cushing Syndrome, Dexamethasone, Humans, Hydrocortisone, Saliva, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.